Study Results from Rochester Institute of Technology Provide New Insights into Leishmaniasis (Treatment of leishmaniasis with chemotherapy and vaccine: a mathematical model).

A recent study conducted by researchers at the Rochester Institute of Technology explores the treatment of leishmaniasis, an infectious disease that manifests in two forms: cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). The current control strategy for leishmaniasis involves chemotherapy drugs, but these have limited efficacy and are associated with adverse effects and drug resistance. While no vaccine is currently available, experimental vaccines such as LEISH-F1+MPL-SE (V) have shown some efficacy when used as drugs for CL patients. The study uses a mathematical model to investigate the extent to which vaccine shots can enhance the efficacy of standard chemotherapy treatment. The findings suggest that combining standard treatment with vaccine injections significantly increases efficacy, with the highest efficacy observed when three vaccine injections are administered. However, there is a resurgence of the disease by the end of the treatment period. Further research is needed to develop more effective treatments for leishmaniasis. [Extracted from the article]

Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)